Cellectis to Report Second Quarter Financial Results on August 6, 2026
Biotechnology company Cellectis announced it will release its financial results for the second quarter of 2026 on August 6, after market close.
New York, NY – Cellectis, a clinical-stage biotechnology firm specializing in genome editing for cell and gene therapies, announced on July 30, 2026, that it will publish its financial results for the second quarter ending June 30, 2026. The results are scheduled to be released after the market closes in the United States on Thursday, August 6, 2026.
The company has stated that a press release detailing the financial performance will be made available on the "Investors" section of its website. Specific details regarding the exact time and any potential webcast or conference call were not provided in the initial announcement, though an email address for investor relations was made public.
Cellectis is focused on developing and commercializing innovative therapies utilizing its proprietary genome editing technologies. The company's pipeline includes various product candidates targeting unmet medical needs. Investors and interested parties are advised to monitor the company's investor relations portal for the upcoming financial report and any related disclosures.
No conference call will be held by Cellectis to discuss these results. The company's investor relations team will be available to respond to inquiries via email. The full press release will also be available for download in PDF format.